We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
신규 편입 · 포트폴리오 비중 0.06%
신규 편입 · 포트폴리오 비중 0.02%
신규 편입 · 포트폴리오 비중 0.01%
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $49.15 · 13 analysts
Stored first · Google News · Yahoo Finance (English)
3 Cash-Producing Stocks We’re Skeptical Of
BofA Securities Adjusts Bruker Price Target to $70 From $65
Bruker Corporation Stock 12‑Month Price Target Raised to $58.08, Implies 3% Downside - TradingView
Bruker Corporation Stock 12‑Month Price Target Raised to $58.08, Implies 3% Downside TradingView
Guggenheim reiterates Bruker stock Buy rating on metrology demand - Investing.com
Guggenheim reiterates Bruker stock Buy rating on metrology demand Investing.com
Bruker Announces Major Strides in 4D Proteomics Performance, Further Advances In Intact and Top-Down Functional Proteoform Analysis, and Innovations in Hybrid Qual/Quant 4D Metabolomics – all to Enable Deeper Insights into Disease Biology - AOL.com
Bruker Announces Major Strides in 4D Proteomics Performance, Further Advances In Intact and Top-Down Functional Proteoform Analysis, and Innovations in Hybrid Qual/Quant 4D Metabolomics – all to Enable Deeper Insights into Disease Biology AOL.com
Bruker Corporation $BRKR Shares Bought by Candriam S.C.A. - MarketBeat
Bruker Corporation $BRKR Shares Bought by Candriam S.C.A. MarketBeat
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 04. | After market close (AMC) | $0.39 | — | — | $853.73M | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $0.11 | — | — | $801.4M | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $0.67 | — | — | $2.39B | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $0.4 | — | — | $1.52B | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 08. | UBS | — | Maintain | Neutral → Neutral | — | UBS: Neutral |
| 2026. 05. 08. | Citigroup | — | Maintain | Neutral → Neutral | — | Citigroup: Neutral |
| 2026. 05. 08. | TD Cowen | — | Maintain | Hold → Hold | — | TD Cowen: Hold |
| 2026. 05. 08. | Barclays | — | Maintain | Overweight → Overweight | — | Barclays: Overweight |
| 2026. 04. 16. | Barclays | — | Maintain | Overweight → Overweight | — | Barclays: Overweight |
| 2026. 04. 15. | Barclays | — | Maintain | Overweight → Overweight | — | Barclays: Overweight |
As of FY2025Q3 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 1,553,054 | $73.16M | 0.12% | — | New position |
| 2 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 952,873 | $34.42M | 0.06% | — | New position |
| 3 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 615,992 | $22.25M | 0.02% | — | New position |
| 4 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 421,625 | $19.86M | 0.03% | — | New position |
| 5 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 56,456 | $15.93M | 0.01% | — | New position |